Fragile X syndrome market to quadruple to $111.9 million in USA and Germany by 2030

According to new research announced today, the fragile X syndrome (FXS) market across the USA and Germany is projected to experience explosive growth, quadrupling from $28.7 million in 2025 to $111.9 million by 2030, a compound annual growth rate (CAGR) of 31.3% (2025-2030), driven by the anticipated launch of two high-priced targeted therapies for FXS in 2027.

Pharma analytics company GlobalData’s latest report, “Fragile X Syndrome: Opportunity Assessment and Forecast -Update,” anticipates a stable market until the projected US launches of Harmony Biosciences’ (Nasdaq: HRMY) Zygel (cannabidiol) and Japanese pharma major Shionogi’s (TYO: 4507) zatolmilast in 2027. Zygel is expected to launch in Germany in 2028, whereas zatolmilast is not anticipated to launch in Germany during the forecast period. These therapies are set to represent the first treatments to be indicated for FXS.

“The introduction of Zygel and zatolmilast could mark a turning point in FXS treatment as, for the first time, there could be therapies offering the potential to address the underlying mechanisms of the disease, a significant unmet need,” commented GlobalData pharma analyst Lorraine Palmer.